M. Rusanova

Immunogenicity of the drug "Live intranasal vaccine for the prevention of pertussis" (GamLPV) with a single use in healthy volunteers

I. Dyakov, A. Medkova, A. A. Lidzhiyeva, 2022, Journal of microbiology, epidemiology and immunobiology.

Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.

W. Haefeli, M. Haag, U. Merle, 2022, The Lancet. Infectious diseases.

Phase 3 Trial of Coronavir (Favipiravir) in Patients with Mild to Moderate COVID-19

T. Soluyanova, R. Oseshnyuk, M. Rusanova, 2020, SSRN Electronic Journal.

Efficacy and safety of favipiravir in a complex therapy of mild to moderate COVID-19

T. Soluyanova, R. Oseshnyuk, S. Shcherbak, 2020 .

Development of a Method and a Scheme for the Use of a Live Recombinant Vaccine "GamLPV". Safety and Tolerability of Double Intranasal Vaccination of Healthy Adult Volunteers

I. Dyakov, S. Smetanina, E. Smolyarchuk, 2022, Drug development & registration.

A Clinical Study of the Safety and Tolerability of Live Nasal Vaccines for the Prevention of Pertussis

I. Dyakov, S. Smetanina, A. Medkova, 2021, Drug development & registration.